Cargando…
An In Vitro Analysis of TKI-Based Sequence Therapy in Renal Cell Carcinoma Cell Lines
The tyrosine kinase inhibitor (TKI) cabozantinib might impede the growth of the sunitinib-resistant cell lines by targeting MET and AXL overexpression in metastatic renal cell carcinoma (mRCC). We studied the role of MET and AXL in the response to cabozantinib, particularly following long-term admin...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058472/ https://www.ncbi.nlm.nih.gov/pubmed/36982721 http://dx.doi.org/10.3390/ijms24065648 |
_version_ | 1785016639531515904 |
---|---|
author | Zaccagnino, Angela Vynnytska-Myronovska, Bozhena Stöckle, Michael Junker, Kerstin |
author_facet | Zaccagnino, Angela Vynnytska-Myronovska, Bozhena Stöckle, Michael Junker, Kerstin |
author_sort | Zaccagnino, Angela |
collection | PubMed |
description | The tyrosine kinase inhibitor (TKI) cabozantinib might impede the growth of the sunitinib-resistant cell lines by targeting MET and AXL overexpression in metastatic renal cell carcinoma (mRCC). We studied the role of MET and AXL in the response to cabozantinib, particularly following long-term administration with sunitinib. Two sunitinib-resistant cell lines, 786-O/S and Caki-2/S, and the matching 786-O/WT and Caki-2/WT cells were exposed to cabozantinib. The drug response was cell-line-specific. The 786-O/S cells were less growth-inhibited by cabozantinib than 786-O/WT cells (p-value = 0.02). In 786-O/S cells, the high level of phosphorylation of MET and AXL was not affected by cabozantinib. Despite cabozantinib hampering the high constitutive phosphorylation of MET, the Caki-2 cells showed low sensitivity to cabozantinib, and this was independent of sunitinib pretreatment. In both sunitinib-resistant cell lines, cabozantinib increased Src-FAK activation and impeded mTOR expression. The modulation of ERK and AKT was cell-line-specific, mirroring the heterogeneity among the patients. Overall, the MET- and AXL-driven status did not affect cell responsiveness to cabozantinib in the second-line treatment. The activation of Src-FAK might counteract cabozantinib activity and contribute to tumor survival and may be considered an early indicator of therapy response. |
format | Online Article Text |
id | pubmed-10058472 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100584722023-03-30 An In Vitro Analysis of TKI-Based Sequence Therapy in Renal Cell Carcinoma Cell Lines Zaccagnino, Angela Vynnytska-Myronovska, Bozhena Stöckle, Michael Junker, Kerstin Int J Mol Sci Article The tyrosine kinase inhibitor (TKI) cabozantinib might impede the growth of the sunitinib-resistant cell lines by targeting MET and AXL overexpression in metastatic renal cell carcinoma (mRCC). We studied the role of MET and AXL in the response to cabozantinib, particularly following long-term administration with sunitinib. Two sunitinib-resistant cell lines, 786-O/S and Caki-2/S, and the matching 786-O/WT and Caki-2/WT cells were exposed to cabozantinib. The drug response was cell-line-specific. The 786-O/S cells were less growth-inhibited by cabozantinib than 786-O/WT cells (p-value = 0.02). In 786-O/S cells, the high level of phosphorylation of MET and AXL was not affected by cabozantinib. Despite cabozantinib hampering the high constitutive phosphorylation of MET, the Caki-2 cells showed low sensitivity to cabozantinib, and this was independent of sunitinib pretreatment. In both sunitinib-resistant cell lines, cabozantinib increased Src-FAK activation and impeded mTOR expression. The modulation of ERK and AKT was cell-line-specific, mirroring the heterogeneity among the patients. Overall, the MET- and AXL-driven status did not affect cell responsiveness to cabozantinib in the second-line treatment. The activation of Src-FAK might counteract cabozantinib activity and contribute to tumor survival and may be considered an early indicator of therapy response. MDPI 2023-03-15 /pmc/articles/PMC10058472/ /pubmed/36982721 http://dx.doi.org/10.3390/ijms24065648 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Zaccagnino, Angela Vynnytska-Myronovska, Bozhena Stöckle, Michael Junker, Kerstin An In Vitro Analysis of TKI-Based Sequence Therapy in Renal Cell Carcinoma Cell Lines |
title | An In Vitro Analysis of TKI-Based Sequence Therapy in Renal Cell Carcinoma Cell Lines |
title_full | An In Vitro Analysis of TKI-Based Sequence Therapy in Renal Cell Carcinoma Cell Lines |
title_fullStr | An In Vitro Analysis of TKI-Based Sequence Therapy in Renal Cell Carcinoma Cell Lines |
title_full_unstemmed | An In Vitro Analysis of TKI-Based Sequence Therapy in Renal Cell Carcinoma Cell Lines |
title_short | An In Vitro Analysis of TKI-Based Sequence Therapy in Renal Cell Carcinoma Cell Lines |
title_sort | in vitro analysis of tki-based sequence therapy in renal cell carcinoma cell lines |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058472/ https://www.ncbi.nlm.nih.gov/pubmed/36982721 http://dx.doi.org/10.3390/ijms24065648 |
work_keys_str_mv | AT zaccagninoangela aninvitroanalysisoftkibasedsequencetherapyinrenalcellcarcinomacelllines AT vynnytskamyronovskabozhena aninvitroanalysisoftkibasedsequencetherapyinrenalcellcarcinomacelllines AT stocklemichael aninvitroanalysisoftkibasedsequencetherapyinrenalcellcarcinomacelllines AT junkerkerstin aninvitroanalysisoftkibasedsequencetherapyinrenalcellcarcinomacelllines AT zaccagninoangela invitroanalysisoftkibasedsequencetherapyinrenalcellcarcinomacelllines AT vynnytskamyronovskabozhena invitroanalysisoftkibasedsequencetherapyinrenalcellcarcinomacelllines AT stocklemichael invitroanalysisoftkibasedsequencetherapyinrenalcellcarcinomacelllines AT junkerkerstin invitroanalysisoftkibasedsequencetherapyinrenalcellcarcinomacelllines |